3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Dermatologic
1
Conditions
Carcinoma, Non-Small-Cell Lung
28
Carcinoma, Renal Cell
19
Melanoma
18
Lung Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
8
Neoplasm Metastasis
8
Hodgkin Disease
7
Colorectal Neoplasms
7
Adenocarcinoma Of Esophagus
7
Stomach Neoplasms
6
Neoplasms
6
Carcinoma, Hepatocellular
6
Triple Negative Breast Neoplasms
5
Prostatic Neoplasms
5
Pancreatic Neoplasms
5
Carcinoma, Transitional Cell
5
Urinary Bladder Neoplasms
4
Rectal Neoplasms
4
Ovarian Neoplasms
4
Nasopharyngeal Carcinoma
4
Endometrial Neoplasms
4
Carcinoma, Merkel Cell
4
Carcinoma, Basal Cell
4
Brain Neoplasms
4
Anus Neoplasms
4
Oropharyngeal Neoplasms
3
Multiple Myeloma
3
Lymphoma, Non-Hodgkin
3
Lymphoma, Large B-Cell, Diffuse
3
Lymphoma
3
Interventions
Cyclophosphamide
9
fludarabine
7
Dexamethasone
7
pomalidomide
6
Rituximab
6
pembrolizumab
5
selinexor
4
obinutuzumab
4
glofitamab
4
Lenalidomide
4
daratumumab
3
belantamab mafodotin
3
Temozolomide
3
Gemcitabine
3
Etoposide
3
Bortezomib
3
zanubrutinib
2
venetoclax
2
tocilizumab
2
fludarabine phosphate
2
enzalutamide
2
cemiplimab
2
carfilzomib
2
abemaciclib
2
PF06821497
2
Mesna
2
Lisaftoclax
2
Injections
2
Immunotherapy, Adoptive
2
Granulocyte Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recurrence
×
Nivolumab
×
30 days
×
Clear all
NCT03686124
2026-05-13
ACTengine
Immatics US, Inc.
Phase 1/2
Recruiting
375 enrolled